Shares of PureTech Health plc (LON:PRTC - Get Free Report) dropped 12.4% on Thursday . The company traded as low as GBX 100.40 ($1.32) and last traded at GBX 103 ($1.36). Approximately 3,018,245 shares were traded during mid-day trading, an increase of 192% from the average daily volume of 1,035,028 shares. The stock had previously closed at GBX 117.60 ($1.55).
Analyst Upgrades and Downgrades
Separately, Jefferies Financial Group restated a "buy" rating and set a GBX 455 ($6.00) price target on shares of PureTech Health in a research report on Monday, December 16th.
Read Our Latest Research Report on PRTC
PureTech Health Trading Up 0.2 %
The company has a quick ratio of 2.51, a current ratio of 3.68 and a debt-to-equity ratio of 45.82. The firm has a market cap of £377.28 million, a price-to-earnings ratio of -5.15 and a beta of 1.02. The company has a 50-day moving average price of GBX 134.79 and a 200 day moving average price of GBX 147.92.
About PureTech Health
(
Get Free Report)
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
See Also
Before you consider PureTech Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.
While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
